REGENXBIO Inc. (RGNX) — Research Snapshot as of October 30, 2026

Market Context

RGNX trades on Nasdaq with a market capitalization of roughly $478M, near the low end of its 52-week range ($5.45–$16.19), and carries a beta of ~1.13, reflecting its high-volatility biotech profile [13], [25]. The stock fell roughly 14% in a single week in late October, and there was noted lack of market enthusiasm ahead of upcoming events [28].

Recent Catalysts (last ~1–3 months)